Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasNeuro-OncologyDiseaseMalignant MeningitisNHL, B-Cell Type, Burkitt's LymphomaSubgroupICD10C79.3C83.7MeSHBurkitt LymphomaMeningeal CarcinomatosisSequenceDA-EPOCH-R(R), Burkitt's lymphomaChemotherapyChemo-substanceMethotrexateChemo-substanceMethotrexateChemo-substanceMethotrexateChemo-substanceMethotrexateNo. Substances1 RadiotherapySupportive therapySupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorRoschewski MDiseaseBurkitt-Lymphom, ZNS-Befall vor Beginn der TherapieOriginLymphoid Malignancies Branch, National Cancer Institute, BethesdaProtocols in Revision 1 protocol foundProtocols under revision.Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231 V1.1)
